Syndax Pharmaceuticals (SNDX) Other Non Operating Income (2015 - 2026)
Syndax Pharmaceuticals (SNDX) recorded quarterly Other Non Operating Income of -$186000.0 in Q1 2026, up 7.46% quarter-over-quarter from -$201000.0 in Q4 2025, and up 15.84% on a YoY basis from -$160570.3 in Q1 2025.
Syndax Pharmaceuticals (SNDX) Other Non Operating Income (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Other Non Operating Income history runs 12 years deep, the most recent figure standing at -$186000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 15.84% year-over-year to -$186000.0; the TTM figure through Mar 2026 stood at -$883000.0 (down 131.76% YoY), while the FY2025 annual figure was -$1.3 million, down 419.43% from the prior year.
- Other Non Operating Income was -$186000.0 for Q1 2026 at Syndax Pharmaceuticals, up from -$201000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $116000.0 in Q1 2022 to a low of -$295000.0 in Q3 2022.
- Historically, Other Non Operating Income has averaged -$112937.5 across 5 years, with a median of -$99500.0 in 2022.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income soared 303.51% in 2022, then slumped 959.38% in 2025.
- A 5-year view of Other Non Operating Income shows it stood at -$106000.0 in 2022, then soared by 48.11% to -$55000.0 in 2023, then sank by 92.73% to -$106000.0 in 2024, then plunged by 89.62% to -$201000.0 in 2025, then gained by 7.46% to -$186000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$186000.0 (Q1 2026), -$201000.0 (Q4 2025), and -$275000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Syndax Pharmaceuticals | 1.69 Bn | 1.34 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -186,000.00 |
| Dec 31, 2025 | -201,000.00 |
| Sep 30, 2025 | -275,000.00 |
| Mar 31, 2025 | -221,000.00 |
| Dec 31, 2024 | -106,000.00 |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | -86,000.00 |
| Mar 31, 2024 | -87,000.00 |
| Dec 31, 2023 | -55,000.00 |
| Sep 30, 2023 | -66,000.00 |
| Jun 30, 2023 | -93,000.00 |
| Mar 31, 2023 | -147,000.00 |
| Dec 31, 2022 | -106,000.00 |
| Sep 30, 2022 | -295,000.00 |
| Jun 30, 2022 | -31,000.00 |
| Mar 31, 2022 | 116,000.00 |
| Dec 31, 2021 | 351,000.00 |
| Sep 30, 2021 | -41,000.00 |
| Jun 30, 2021 | -50,000.00 |
| Mar 31, 2021 | -57,000.00 |